Professor, Psychiatry, Yale University School of Medicine

Psychiatry

Kimberly Yonkers practices Psychiatry. She studied medicine at Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is one of the top medical schools in the US. Columbia University College of Physicians & Surgeons has a rank of 8 in research and a 52 in primary care Doctor Kimberly A. Yonkers, MD is a published doctor and has 97 publications published. The lastest was: 'Assessing unipolar mood disorders in women.' Kimberly Yonkers is registered with Medicare and accepts Medicare payments.

Publications

---

• Perinatal substance use: A prospective evaluation of abstinence and relapse.
• Progesterone Reduces Cocaine Use in Postpartum Women with a Cocaine Use Disorder: A Randomized,Double-Blind Study.
• Clinical correlates of prescription opioid analgesic use in pregnancy.
• Pregnant Women With Posttraumatic Stress Disorder and Risk of Preterm Birth.
• The prevalence and severity of depressive symptoms along the spectrum of unipolar depressive Disorders: a post hoc analysis.
• Addressing concerns about the inclusion of premenstrual dysphoric Disorder in DSM-5.
• A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight.
• Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive Disorder.
• ISPMD consensus on the management of premenstrual Disorders.
• Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors.
• The possible effects of Depressive symptoms on risk of preterm birth are clouded by lack of control over confounding factors.
• Prenatal hazardous substance use and adverse birth outcomes.
• Motivational enhancement therapy coupled with cognitive behavioral therapy versus brief advice: a randomized trial for treatment of hazardous substance use in pregnanc...
• Premenstrual dysphoric Disorder: evidence for a new category for DSM-5.
• Does Antidepressant Use Attenuate the Risk of a Major Depressive Episode in Pregnancy?
• Diagnosis, pathophysiology, and management of mood Disorders in pregnant and postpartum women.
• Generalized Anxiety disorder: course and risk factors in pregnancy.
• Perinatal depression and birth outcomes in a Healthy Start project.
• The ties that bind: maternal-infant interactions and the neural circuitry of postpartum depression.
• Screening for prenatal substance use: development of the Substance Use Risk Profile-Pregnancy scale.
• Do the PHQ-8 and the PHQ-2 accurately screen for depressive Disorders in a sample of pregnant women?
• A treatment for substance abusing pregnant women.
• Typical somatic symptoms of pregnancy and their impact on a diagnosis of major depressive Disorder.
• The expanding medical and behavioral resources with access to care for everyone health plan.
• Evaluation of a social support measure that may indicate risk of depression during pregnancy.
• Depression screening of perinatal women: an evaluation of the healthy start depression initiative.
• Success of Mental health referral among pregnant and postpartum women with psychiatric distress.
• Parsing risk for the use of selective serotonin reuptake inhibitors in pregnancy.
• Update on research and treatment of premenstrual dysphoric Disorder.
• Pharmacologic treatment of postpartum women with new-onset major depressive Disorder: a randomized controlled trial with paroxetine.
• Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool.
• Co-morbid major depression and generalized anxiety Disorders in the National Comorbidity Survey follow-up.
• Symptom features of postpartum depression: are they distinct?
• Integration of medical and psychological treatment within the primary health care setting.
• The treatment of women suffering from depression who are either pregnant or breastfeeding.
• Differences in symptom scores and health outcomes in premenstrual syndrome.
• Effects of posttraumatic stress Disorder on pregnancy outcomes.
• Using the daily record of severity of problems as a screening instrument for premenstrual syndrome.
• Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies.
• Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric Disorder?
• Evaluating the criteria used for identification of PMS.
• Symptoms of posttraumatic stress Disorder in a community sample of low-income pregnant women.
• Symptom-onset treatment for women with premenstrual dysphoric Disorder.
• Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs.
• Treatment of premenstrual dysphoric Disorder with a new drospirenone-containing oral contraceptive formulation.
• Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric Disorder.
• Influence of psychiatric comorbidity on recovery and recurrence in generalized Anxiety disorder, social phobia, and panic disorder: a 12-year prospective study.
• Pretreatment pattern of symptom expression in premenstrual dysphoric Disorder.
• Luteal phase treatment of premenstrual dysphoric Disorder improves symptoms that continue into the postmenstrual phase.
• Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive Disorder.
• Risk factors for premenstrual dysphoric Disorder in a community sample of young women: the role of traumatic events and posttraumatic stress Disorder.
• Paroxetine controlled release for premenstrual dysphoric Disorder: a double-blind, placebo-controlled trial.
• Management strategies for PMS/PMDD.
• New trends in the treatment of anxiety Disorders.
• Management of Bipolar disorder during pregnancy and the postpartum period.
• Screening for and detection of depression, panic Disorder, and PTSD in public-sector obstetric clinics.
• Premenstrual Disorders: bridging research and clinical reality.
• Health and economic impact of the premenstrual syndrome.
• Special issues related to the treatment of depression in women.
• Paroxetine treatment of mood Disorders in women: premenstrual dysphoric disorder and hot flashes.
• Chronicity, relapse, and illness--course of panic disorder, social phobia, and generalized Anxiety disorder: findings in men and women from 8 years of follow-up.
• More sleep cycles in the mid-luteal phase of a healthy control.
• Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric Disorder.
• The pharmacologic treatment of depression: is gender a critical factor?
• Review of fluoxetine and its clinical applications in premenstrual dysphoric Disorder.
• Review: progesterone or progesterone lead to a marginal reduction in premenstrual syndrome symptoms.
• A descriptive analysis of minor depression.
• Onset and persistence of postpartum depression in an inner-city maternal health clinic system.
• Venlafaxine in the treatment of premenstrual dysphoric Disorder.
• An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women.
• Generalized Anxiety disorder in women.
• Gender differences in chronic Major and double depression.
• Gender differences in treatment response to sertraline versus imipramine in chronic depression.
• Factors predicting the clinical course of generalised Anxiety disorder.
• Psychosocial functioning in women with premenstrual dysphoric Disorder before and after treatment with sertraline or placebo.
• Lack of relationship between menstrual cycle phase and mood in a sample of women with rapid cycling Bipolar disorder.
• Medical management of premenstrual dysphoric Disorder.
• Adrenergic receptors in premenstrual dysphoric Disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase s...
• Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive Disorder.
• Adrenergic receptors in premenstrual dysphoric Disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of lut...
• Is the course of panic Disorder the same in women and men?
• Assessing unipolar mood Disorders in women.
• Symptomatic improvement of premenstrual dysphoric Disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative St...
• A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.
• Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.
• The undertreatment of dysthymia.
• Anxiety symptoms and anxiety Disorders: how are they related to premenstrual Disorders?
• The psychopharmacological treatment of nonmajor mood Disorders.
• Antidepressants in the treatment of premenstrual dysphoric Disorder.
• The association between premenstrual dysphoric disorder and other mood Disorders.
• The infrequency of "pure culture" diagnoses among the anxiety Disorders.
• Description of antipanic therapy in a prospective longitudinal study.
• Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric Disorder.
• Phenomenology and course of generalised Anxiety disorder.
• Paroxetine as a treatment for premenstrual dysphoric Disorder.
• Sertraline in the treatment of premenstrual dysphoric Disorder.

Schools

---

• Columbia University College of Physicians And Surgeons

• St LukeS Hospital

• McLean Hospital Harvard University

Conditions Treated

---

• Alcohol-Induced Mental Disorders
• Alcoholism (Alcohol Dependence)
• Anxiety
• Bipolar Disorder
• View All

Doctors Specialties

---

• Psychiatry

Accepted Insurances

---

Education

---

• St Luke's-Roosevelt Hospital Center
• Columbia University College of Physicians & Surgeons

Drug Facts

---

NPI NUMBER		1184613952
NPPES Provider LastName		YONKERS
NPPES Provider FirstName		KIMBERLY
NPPES Provider ZIPCode		065102600
NPPES Provider State		CT
Specialty Description		Psychiatry
Total Claim Count		24.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1184613952
Last Name Of The Provider	YONKERS
First Name Of The Provider	KIMBERLY
View All

Similar Doctors

---

	Dr. James Charney, MD This Doctor is OpenDoctor Recommended.
	Dr. Janet A. Madigan, MD This Doctor is OpenDoctor Recommended.
	Dr. Seth M. Powsner, MD This Doctor is OpenDoctor Recommended.
	Dr. Srinivas B. Muvvala, MD This Doctor is OpenDoctor Recommended.
	Dr. Mary E. Savage, MD This Doctor is OpenDoctor Recommended.
	Dr. Bruce E. Wexler, MD This Doctor is OpenDoctor Recommended.
	Dr. Arie Kaffman, MD
	Dr. Rosemary Balsam, MD
	Dr. Howard V. Zonana, MD This Doctor is OpenDoctor Recommended.
	Dr. Gilberto E. Zayas, MD
	Dr. Paul Y. Geha, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog